C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients

Zimmerman E; Anty R; Tordjman J; Verrijken A; Gual P; Tran A; Ianelli A; Gugenheim J; Bedossa P; Franque S; Le Marchand-Brustel Y; Clement K; Van Gaal L; Sørensen TIA; Jess T
Journal
J Hepatol
Paper attributed to Project(s)

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a major hepatic consequence of obesity. It has been suggested that high sensitivity C-reactive protein (hs-CRP) is an obesity-independent surrogate marker of severity of NAFLD, especially development of non-alcoholic steato-hepatitis (NASH), but this remains controversial. We aimed to investigate if associations between various features of NAFLD and hs-CRP are independent of body mass index (BMI) in its broad range among obese patients.

METHODS: A total of 627 obese adults (80% females) representing three cohorts from France and Belgium, had information on liver histology obtained from liver biopsies and measures of hs-CRP and BMI. We investigated if the different features of NAFLD and BMI, respectively, were associated with hs-CRP, with and without mutual adjustments using linear regression.

RESULTS: BMI and hs-CRP were strongly associated. Per every 10% increase in BMI the hs-CRP-level increased by 19-20% (P<0.001), and adjusting for NAFLD-stage (including no-NAFLD) did not influence the association. We found no BMI-independent association between NASH and hs-CRP. However, a positive association between degree of steatosis and hs-CRP was observed (p⩽0.05) and this effect remained significant after adjusting for BMI, lobular inflammation, hepatocyte ballooning, and fibrosis. We found no significant associations between the other features of NAFLD and hs-CRP.

CONCLUSIONS: This study indicates that it is the accumulation of fat -both in the adipose tissue and as liver steatosis -that leads to increased hs-CRP levels among obese patients. Thus, hs-CRP may be a marker of steatosis, but not severity of NAFLD, in obese patients.

DANORC is supported by the
The Danish Council for Strategic Research
Institute of Preventive Medicine
Frederiksberg Hospital
Nordre Fasanvej 57
2000 Frederiksberg
Denmark
Tel.: +45 38163025